Avibactam
| 證據等級: L5 | 預測適應症: 6 個 |
目錄
Avibactam: Drug Repurposing Evaluation — No TxGNN Predictions Available
One-Sentence Summary
Avibactam (DB09060) is a β-lactamase inhibitor typically used in combination antibiotic therapies for resistant gram-negative bacterial infections. The TxGNN model has not generated any predicted indications for this compound in the current Evidence Pack, and no supporting clinical trial or literature evidence is available for evaluation at this time.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not recorded in current dataset |
| Predicted New Indication | None |
| TxGNN Prediction Score | N/A |
| Evidence Level | N/A |
| Finland Market Status | Not marketed |
| Number of Authorizations | 0 |
| Recommended Decision | Hold |
Conclusion and Next Steps
Decision: Hold
Rationale: The current Evidence Pack contains no TxGNN predicted indications for Avibactam, and critical foundational data — including mechanism of action, original approved indication, and safety warnings — are all absent. A repurposing evaluation cannot meaningfully proceed without these elements.
To proceed, the following is needed:
- TxGNN predictions: Run the prediction pipeline for Avibactam (DB09060) to generate candidate new indications
- Mechanism of action (MOA): Retrieve from DrugBank API to enable mechanistic plausibility analysis
- Safety data: Download and parse the package insert PDF from TFDA official website to obtain warnings and contraindications
- Original approved indication: Confirm from TFDA or EMA/FDA regulatory sources
- DDI data: Query drug interaction database (current query returned no results)
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.